Prevention of relapse of Crohn's disease

Inflammatory Bowel Diseases

Volumn 6, Issue 4, 2000, Pages 321-328

  Sutherland, Lloyd R ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b NONE   (Canada)

Author keywords

Crohn's disease, medications; Crohn's disease, prevention of relapse in; Crohn's disease, treatment

Indexed keywords

BUDESONIDE; GASTROINTESTINAL AGENT; MESALAZINE;

CROHN DISEASE; HUMAN; RECURRENT DISEASE; REVIEW;

BUDESONIDE; CROHN DISEASE; GASTROINTESTINAL AGENTS; HUMANS; MESALAMINE; RECURRENCE;

EID: 19244376464     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1002/ibd.3780060410     Document Type: Article

References (5)

1. Summers RW, Switz DM, Sessions JT Jr., et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979;77:847-69.
2. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1994;86:249-66.
3. Farmer RG, Whelan G, Fazio VW. Long-term follow-up of patients with Crohn's disease. Relationship between the clinical pattern and prognosis. Gastroenterology 1985;88:1818-25.
4. Olaison G, Smedh K, Sjodahl R. Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. Gut 1992;33:331-5.
5. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990; 99:956-63.